AHA Journals, Author Interviews, Biomarkers, Brigham & Women's - Harvard, Heart Disease / 27.02.2024
Brigham Researchers Developing Novel Glycan Marker to Predict Cardiovascular Disease
MedicalResearch.com Interview with:
Rosangela Akemi Hoshi, Ph.D.
Lemann Foundation Cardiovascular Research Postdoctoral Fellowship
Center for Lipid Metabolomics
Divisions of Preventive and Cardiovascular Medicine
Brigham and Women's Hospital
Boston, MA
MedicalResearch.com: What is the background for this study? Would you describe the IgG N-glycan profile?
Response: Glycans are sugar coatings of proteins, made of monosaccharide building blocks, that are involved in a variety of biological pathways. Different sugar structures can dictate or modify the protein’s activity through specific interactions with cellular receptors. For example, proteins lacking glycans have a reduced level or a complete loss of function. Glycans are of such importance that the 2022 Nobel Prize in chemistry was awarded for glycan-based science.
In this study, we examined glycans attached to Immunoglobulins G (IgG) and their link with incidence of cardiovascular disease (CVD) due to their impact on IgG inflammatory properties. Since inflammation is not only a cause, but also an aggravating factor and a mediator of a worse prognosis in cardiometabolic disorders and CVD, we investigated whether different glycan structures may characterize an at-risk phenotype for CVD development.
Determining glycan profiles involved in multiple conditions can serve prognostic and diagnostic purposes. Yet, unlike other types of macromolecules, glycans are still not as much explored, characterizing a promising but underappreciated class that should be further investigated.
(more…)